Amgen Inc. $AMGN Shares Sold by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 4.7% during the third quarter, HoldingsChannel.com reports. The fund owned 178,903 shares of the medical research company’s stock after selling 8,819 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Amgen were worth $50,246,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Legacy Investment Solutions LLC acquired a new position in Amgen in the 2nd quarter valued at about $27,000. Evelyn Partners Investment Management LLP purchased a new position in shares of Amgen in the 2nd quarter valued at approximately $32,000. Howard Hughes Medical Institute acquired a new position in shares of Amgen in the second quarter valued at approximately $32,000. Quaker Wealth Management LLC raised its position in Amgen by 200.0% during the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock worth $34,000 after buying an additional 240 shares during the last quarter. Finally, Nvwm LLC raised its holdings in Amgen by 893.3% during the second quarter. Nvwm LLC now owns 149 shares of the medical research company’s stock worth $42,000 after purchasing an additional 134 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a dividend increase to $2.52, reinforcing its income profile and making the stock more attractive to dividend-focused investors. This supports longer-term investor demand. Amgen (NASDAQ:AMGN) Has Announced That It Will Be Increasing Its Dividend To $2.52
• Positive Sentiment: Amgen expanded its obesity/GLP‑1 strategy via a collaboration with Ro, signaling potential new mid-term revenue streams if programs progress. Pipeline progress tends to boost investor sentiment for growth prospects. Amgen (AMGN) expands obesity strategy with Ro collaboration on GLP-1 therapies
• Positive Sentiment: The stock recently hit a 52-week high, reflecting recent buyer interest and validation of recent corporate moves and sentiment around the pipeline. Amgen stock hits 52-week high at $346.41
• Neutral Sentiment: Zacks notes AMGN is a trending stock on its platform, outlining investor attention and search interest but providing no new catalyst; useful context on market interest but not a direct driver. Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
• Neutral Sentiment: Analyst commentary and deep-dive pieces (e.g., Seeking Alpha on MariTide obesity/T2D potential) highlight upside from R&D, but these are longer‑horizon, research-driven views rather than immediate catalysts. Amgen: A Buy In 2026 On Exciting MariTide Obesity – T2D Potential
• Negative Sentiment: Sagebrush has sued Amgen over disputes tied to the 340B program, introducing legal, reimbursement and stakeholder-risk that could pressure margins or create uncertainty around commercial terms. Litigation and policy disputes can weigh on near-term sentiment. Sagebrush sues Amgen over 340B program row
• Negative Sentiment: Sanford C. Bernstein downgraded Amgen to a Hold / lowered its rating, which can trigger selling or reduced conviction among institutional investors and contribute to downward pressure. Bernstein downgrades Amgen (AMGN) to a Hold

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the sale, the senior vice president owned 7,225 shares of the company’s stock, valued at $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Rachna Khosla sold 890 shares of Amgen stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the transaction, the senior vice president owned 7,082 shares of the company’s stock, valued at $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 10,908 shares of company stock worth $3,674,966. Insiders own 0.76% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Royal Bank Of Canada boosted their target price on Amgen from $330.00 to $335.00 and gave the stock an “outperform” rating in a research report on Thursday, January 8th. UBS Group upgraded Amgen to a “strong-buy” rating in a research note on Wednesday, January 7th. Sanford C. Bernstein lowered Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective on the stock. in a report on Tuesday. Wall Street Zen raised Amgen from a “buy” rating to a “strong-buy” rating in a report on Monday, December 15th. Finally, Morgan Stanley decreased their target price on shares of Amgen from $329.00 to $304.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen presently has an average rating of “Moderate Buy” and an average price target of $339.24.

Amgen Stock Performance

NASDAQ AMGN opened at $344.75 on Friday. The business has a 50 day moving average price of $332.07 and a 200 day moving average price of $307.54. The company has a market capitalization of $185.64 billion, a P/E ratio of 26.64, a PEG ratio of 3.09 and a beta of 0.45. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $349.98. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating the consensus estimate of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The company had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. During the same quarter in the prior year, the company earned $5.58 earnings per share. Amgen’s revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Sell-side analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. Amgen’s dividend payout ratio (DPR) is presently 77.90%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.